Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477))

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cell

• Publication date

  2014-04-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CELL.2014.04.004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

  2013cited by this paper
• Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.

  2013influential reference
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.

  2013cited by this paper
• Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

  2012cited by this paper
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Melanoma genome sequencing reveals frequent PREX2 mutations

  2012cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA.

  2012cited by this paper
• Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

  2012cited by this paper
• Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

  2012cited by this paper
• Mutual exclusivity analysis identifies oncogenic network modules.

  2012cited by this paper
• Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

  2012cited by this paper
• Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

  2012influential reference
• Emerging insights into the molecular and cellular basis of glioblastoma.

  2012cited by this paper
• MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

  2012cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012cited by this paper
• Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011influential reference
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

  2011cited by this paper
• An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma.

  2011cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

  2011cited by this paper
• GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

  2011influential reference
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010influential reference
• Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

  2010cited by this paper
• PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

  2010cited by this paper
• The widespread regulation of microRNA biogenesis, function and decay

  2010cited by this paper
• ARID1A mutations in endometriosis-associated ovarian carcinomas.

  2010cited by this paper
• Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations

  2009cited by this paper
• Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival

  2009cited by this paper
• IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis.

  2007cited by this paper
• Genetic pathways to primary and secondary glioblastoma.

  2007cited by this paper
• Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

  2006cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper
• Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.

  2001cited by this paper
• Isolation and characterization of a novel gene deleted in DiGeorge syndrome.

  1995cited by this paper
• A complete description of the EGF-receptor exon structure: implication in oncogenic activation and domain evolution.

  1993cited by this paper

• Advances in Pharmacological Strategies for Brain Tumors: Molecular Insights and Therapeutic Innovations

  2026cites this paper
• Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood–Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment

  2025cites this paper
• Immunohistochemical expression of transient receptor potential vanilloid 1 in World Health Organization grade IV astrocytoma, oral squamous cell carcinoma and bladder carcinoma

  2025cites this paper
• Reprogramming the Apoptosis–Autophagy Axis in Glioblastoma: The Central Role of the Bcl-2:Beclin-1 Complex and Survival Signalling Networks

  2025cites this paper
• Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review

  2024cites this paper
• Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.

  2024cites this paper
• Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy

  2024cites this paper
• The translatome of glioblastoma

  2024cites this paper
• Application of single cell sequencing technology in ovarian cancer research (review)

  2024cites this paper
• A Probabilistic Approach to Estimate the Temporal Order of Pathway Mutations Accounting for Intra-Tumor Heterogeneity

  2024cites this paper
• Glioblastoma: A molecular insight into current discoveries and treatment directions

  2024cites this paper
• The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas

  2023cites this paper
• Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET

  2023cites this paper
• A novel gene, TARDBP, and the protein it encodes can predict glioma patient prognosis and establish a prediction model

  2023cites this paper
• Personalised therapeutic approaches to glioblastoma: A systematic review

  2023cites this paper
• Over one year of survival difference between distinct cohorts of glioblastoma patients

  2023cites this paper
• Association of RNA-modification “writer” genes with prognosis and response to immunotherapy in patients with low-grade glioma

  2023cites this paper
• G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells

  2023cites this paper
• Functional and Molecular Heterogeneity in Glioma Stem Cells Derived from Multiregional Sampling

  2023cites this paper
• Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

  2023cites this paper
• Cell-free therapy based on extracellular vesicles: a promising therapeutic strategy for peripheral nerve injury

  2023cites this paper
• Preclinical and Clinical Use of Indigenously Developed 99mTc-Diethylenetriaminepentaacetic Acid-Bis-Methionine: l-Type Amino Acid Transporter 1-Targeted Single Photon Emission Computed Tomography Radiotracer for Glioma Management.

  2023cites this paper
• SPOPL induces tumorigenicity and stemness in glioma stem cells by activating Notch signaling

  2023cites this paper
• Role of Non-Receptor-Type Tyrosine Phosphatases in Brain-Related Diseases

  2023cites this paper
• Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.

  2023cites this paper
• Spatial cellular architecture predicts prognosis in glioblastoma

  2023cites this paper
• AXL is required for hypoxia-mediated hypoxia-inducible factor-1 alpha function in glioblastoma

  2023cites this paper
• Characteristic analysis and identification of novel molecular biomarkers in elderly glioblastoma patients using the 2021 WHO Classification of Central Nervous System Tumors

  2023cites this paper
• Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene

  2022cites this paper
• Pervasive conditional selection of driver mutations and modular epistasis networks in cancer

  2022cites this paper
• Quaking Gene Expression as a Prognostic Marker in Neural Inflammation Disorders

  2022cites this paper
• Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker

  2022cites this paper
• Epigenetic basis for PARP mutagenesis in glioblastoma: A review.

  2022cites this paper
• Predicting Blood–Brain Barrier Permeation of Erlotinib and JCN037 by Molecular Simulation

  2022cites this paper
• Glutathione (GSH) conjugated Bi2S3 NPs as a promising radiosensitizer against glioblastoma cancer cells

  2022cites this paper
• Identification of potential driver mutations in glioblastoma using machine learning

  2022cites this paper
• Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma

  2022influential citation
• Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma

  2022cites this paper
• The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers

  2022influential citation
• Diagnostic Value of Nestin Expression in Adult Gliomas

  2022cites this paper
• Expression and estrogen regulation of G protein-coupled estrogen receptor in human glioblastoma cells

  2022cites this paper
• Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis

  2022cites this paper
• CD44 Depletion in Glioblastoma Cells Suppresses Growth and Stemness and Induces Senescence

  2022cites this paper
• Basic premises: searching for new targets and strategies in diffuse gliomas

  2022influential citation
• Co-dependencies in the tumor immune microenvironment

  2022cites this paper
• Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review)

  2022cites this paper
• Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma

  2022cites this paper
• Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma

  2022cites this paper
• Glycosylation modification identifies novel molecular phenotypes and prognostic stratifications of glioma.

  2022cites this paper
• The miR-183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification

  2022cites this paper
• Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients

  2022cites this paper
• Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma

  2022cites this paper
• Advances in local therapy for glioblastoma — taking the fight to the tumour

  2022cites this paper
• Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma

  2022cites this paper
• New Approaches with Precision Medicine in Adult Brain Tumors

  2022influential citation
• Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells

  2022cites this paper
• Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma

  2022cites this paper
• CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather

  2021cites this paper
• Intraarterial delivery of virotherapy for glioblastoma.

  2021cites this paper
• Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations.

  2021cites this paper
• Therapeutic strategies of recurrent glioblastoma and its molecular pathways ‘Lock up the beast’

  2021cites this paper
• SH3KBP1 Promotes Glioblastoma Tumorigenesis by Activating EGFR Signaling

  2021cites this paper
• SH2B3, Transcribed by STAT1, Promotes Glioblastoma Progression Through Transducing IL-6/gp130 Signaling to Activate STAT3 Signaling

  2021cites this paper
• BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage

  2021cites this paper
• Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker

  2021cites this paper
• p53 mutations exhibit sex specific gain-of-function activity in gliomagenesis

  2021cites this paper
• Loss of FAM60A attenuates cell proliferation in glioma via suppression of PI3K/Akt/mTOR signaling pathways

  2021cites this paper
• Identification of glioblastoma immune subtypes and immune landscape based on a large cohort

  2021cites this paper
• New Glioma Molecular Classification for Precise Therapeutic Decision Based on Spatially-Resolved Proteogenomics Guided by MALDI-MSI and Clinical Data Integration

  2021cites this paper
• Genomic Medicine in Central Nervous System Tumors

  2021cites this paper
• Early and Bi-hemispheric Seizure Onset in a Rat Glioblastoma Multiforme Model.

  2021cites this paper
• Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial

  2021cites this paper
• EZH2 inhibition in glioblastoma stem cells increases the expression of neuronal genes and the neuronal developmental regulators ZIC2, ZNF423 and MAFB

  2021cites this paper
• Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas

  2021cites this paper
• A Notch inhibitor plus Resveratrol induced blockade of autophagy drives glioblastoma cell death by promoting a switch to apoptosis.

  2021cites this paper
• A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors

  2020influential citation
• Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers.

  2020cites this paper
• Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme

  2020cites this paper
• Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells

  2020cites this paper
• miRNA-mediated loss of m6A increases nascent translation in glioblastoma

  2020cites this paper
• Rapid fully-automated assay for routine molecular diagnosis of BRAF mutations for personalized therapy of low grade gliomas

  2020cites this paper
• New strategies for managing adult gliomas

  2020cites this paper
• The histological representativeness of glioblastoma tissue samples

  2020cites this paper
• Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas

  2020cites this paper
• Investigating the Influence of the Comprehensive mRNA Expression Levels of Prognostic Genes on Patient Survival in Every Type of Cancer

  2020cites this paper
• Rapid Proteomic Profiling by MALDI‐TOF Mass Spectrometry for Better Brain Tumor Classification

  2020cites this paper
• Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab

  2020cites this paper
• Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

  2020cites this paper
• A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level

  2020cites this paper
• Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.

  2020cites this paper
• Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis

  2019cites this paper
• 3D spatial organization and network-guided comparison of mutation profiles in Glioblastoma reveals similarities across patients

  2019cites this paper
• From genome to phenome: Predicting multiple cancer phenotypes based on somatic genomic alterations via the genomic impact transformer

  2019cites this paper
• Role of MEK-ERK signaling mediated adhesion of glioma cells to extra-cellular matrix: Possible implication on migration and proliferation

  2019cites this paper
• Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment

  2019cites this paper
• Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas

  2019cites this paper
• RETRACTED: The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models

  2019cites this paper
• The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy

  2019cites this paper
• Efficient algorithms to discover alterations with complementary functional association in cancer

  2018cites this paper
• Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations.

  2018cites this paper